Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

8561. Darbepoetin alfa (Aranesp®) - For the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy

Darbepoetin alfa (Aranesp®) - For the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy Darbepoetin alfa (Aranesp®) - For the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy Darbepoetin alfa (Aranesp®) - For the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy All Wales Medicines Strategy Group (AWMSG) Record (...) Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Darbepoetin alfa (Aranesp®) - For the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). 2003

2003 Health Technology Assessment (HTA) Database.

8562. Computed tomography in screening for lung cancer. Version 2.0 - early assessment briefs (Alert)

Computed tomography in screening for lung cancer. Version 2.0 - early assessment briefs (Alert) Computed tomography in screening for lung cancer. Version 2.0 - early assessment briefs (Alert) Computed tomography in screening for lung cancer. Version 2.0 - early assessment briefs (Alert) Swedish Council on Technology Assessment in Health Care Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Swedish Council on Technology Assessment in Health Care. Computed tomography in screening for lung cancer. Version 2.0 - early assessment briefs (Alert) Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 2003 Authors' objectives This review aims to assess the available evidence on computed tomography in screening for lung cancer. This is an update of a 2002 report. Authors' conclusions Currently, there is good scientific

2003 Health Technology Assessment (HTA) Database.

8563. Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer

Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer Iskedjian M, Hemels M, Einarson T R, Vicente C, Iscoe N, Fleshner N Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Iskedjian M, Hemels M, Einarson T R, Vicente C, Iscoe N, Fleshner N. Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2003: 65 Authors' objectives This report aims to review the clinical evidence for the use of luteinizing

2003 Health Technology Assessment (HTA) Database.

8564. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer

Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 18(15). 2003 Authors

2003 Health Technology Assessment (HTA) Database.

8565. Opioid use in chronic non-cancer pain: proposal for a common approach across Canada

Opioid use in chronic non-cancer pain: proposal for a common approach across Canada Opioid use in chronic non-cancer pain: proposal for a common approach across Canada Opioid use in chronic non-cancer pain: proposal for a common approach across Canada Workers' Compensation Board of British Columbia Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Workers (...) ' Compensation Board of British Columbia. Opioid use in chronic non-cancer pain: proposal for a common approach across Canada. Richmond, BC: WorkSafe BC 2003: 27 Authors' objectives This review is a call for a common approach across Canada to opioid use in chronic non-cancer pain. Authors' conclusions Opioids are not the drug of choice for chronic non-cancer pain, but in an appropriate clinical setting, oral opioids are currently considered an acceptable medical intervention for chronic benign painful

2003 Health Technology Assessment (HTA) Database.

8566. Screening for lung cancer: updated recommendations from the Canadian Task Force on Preventive Health Care

Screening for lung cancer: updated recommendations from the Canadian Task Force on Preventive Health Care Screening for lung cancer: updated recommendations from the Canadian Task Force on Preventive Health Care Screening for lung cancer: updated recommendations from the Canadian Task Force on Preventive Health Care Palda V A, Van Spall H G C, with the Canadian Task Force on Preventive Health Care Record Status This is a bibliographic record of a published health technology assessment (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Palda V A, Van Spall H G C, with the Canadian Task Force on Preventive Health Care. Screening for lung cancer: updated recommendations from the Canadian Task Force on Preventive Health Care. London, Ontario: Canadian Task Force on Preventive Health Care (CTFPHC) 2003: 22 Authors' objectives This review updates the 1994 recommendations of the Canadian Task Force on Preventive Health Care for lung cancer screening

2003 Health Technology Assessment (HTA) Database.

8567. The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations

The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations Alkhenizan A, Palda V A, and the Canadian Task Force on Preventive Health Care Record Status (...) This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alkhenizan A, Palda V A, and the Canadian Task Force on Preventive Health Care. The role of vitamin E supplements in the prevention of cardiovascular disease and cancer: systematic review and recommendations. London, Ontario: Canadian Task Force on Preventive Health Care (CTFPHC) 2003: 36 Authors' objectives This report aims to establish evidence

2003 Health Technology Assessment (HTA) Database.

8568. Brachytherapy for prostate cancer treatment

Brachytherapy for prostate cancer treatment Brachytherapy for prostate cancer treatment Brachytherapy for prostate cancer treatment Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia (...) Marti S. Brachytherapy for prostate cancer treatment. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2003 Authors' objectives This study aims to provide an overview of the effectiveness of brachytherapy for prostate cancer treatment. Authors' conclusions If the therapeutic decision is to perform an active treatment (as opposed to observation and medical control), the patients should be appropriately informed of the scope and potential adverse effects

2003 Health Technology Assessment (HTA) Database.

8569. Effect of supplemental use of antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cancer

Effect of supplemental use of antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cancer Effect of supplemental use of antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cancer Effect of supplemental use of antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cancer Shekelle P, Coulter I, Hardy M, Morton SC Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shekelle P, Coulter I, Hardy M, Morton SC. Effect of supplemental use of antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cancer. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 75. 2003 Authors' objectives The objective of this report was to conduct a comprehensive literature review

2003 Health Technology Assessment (HTA) Database.

8570. FDG positron emission tomography for evaluating breast cancer

FDG positron emission tomography for evaluating breast cancer FDG positron emission tomography for evaluating breast cancer FDG positron emission tomography for evaluating breast cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 (...) years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. FDG positron emission tomography for evaluating breast cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 18(14). 2003 Authors' objectives This Assessment updates the 2001 TEC Assessment on FDG PET imaging for evaluating breast cancer (Vol. 16, No. 5). This Assessment is organized into 3 parts, as follows: Part I: Initial Staging

2003 Health Technology Assessment (HTA) Database.

8571. Molecular diagnosis for hereditary cancer predisposing syndromes: genetic testing and clinical impact

Molecular diagnosis for hereditary cancer predisposing syndromes: genetic testing and clinical impact Molecular diagnosis for hereditary cancer predisposing syndromes: genetic testing and clinical impact Molecular diagnosis for hereditary cancer predisposing syndromes: genetic testing and clinical impact Ho C, Banerjee S, Mensinkai S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Ho C, Banerjee S, Mensinkai S. Molecular diagnosis for hereditary cancer predisposing syndromes: genetic testing and clinical impact. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2003: 82 Authors' objectives To assess the evidence regarding the availability, cost, and analytical and clinical validity of genetic tests for screening and diagnosis of hereditary cancer predisposing syndromes. To document the impact

2003 Health Technology Assessment (HTA) Database.

8572. Liquid-based cytology and human papillomavirus testing in cervical cancer screening

Liquid-based cytology and human papillomavirus testing in cervical cancer screening Liquid-based cytology and human papillomavirus testing in cervical cancer screening Liquid-based cytology and human papillomavirus testing in cervical cancer screening Noorani H Z, Brown A, Skidmore B, Stuart G C E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Noorani H Z, Brown A, Skidmore B, Stuart G C E. Liquid-based cytology and human papillomavirus testing in cervical cancer screening. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2003: 85 Authors' objectives To compare the diagnostic accuracy of liquid-based cytology (LBC) and human papillomavirus (HPV) testing with that of Papanicolaou (Pap) smears in the detection of precancerous or malignant cervical lesions. To evaluate the comparative cost and cost

2003 Health Technology Assessment (HTA) Database.

8573. Counseling to prevent skin cancer

Counseling to prevent skin cancer Counseling to prevent skin cancer Counseling to prevent skin cancer Helfand M, Krages K P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Helfand M, Krages K P. Counseling to prevent skin cancer. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services Task Force Systematic (...) Evidence Review. 2003 Authors' objectives This study addresses the following questions: - Is reducing sun exposure effective in reducing melanoma? - Does the use of sunlamps and tanning beds increase risk for melanoma? - Is the use of sunscreen effective in preventing nonmelanoma skin cancer and melanoma? - Do sun protection behaviors have significant adverse effects? - Is skin self-examination effective in reducing the incidence of melanoma? - Does counseling by a primary care clinician increase sun

2003 Health Technology Assessment (HTA) Database.

8574. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review Hummel S, Paisley S, Morgan A, Currie E, Brewer N Citation Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost (...) -effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technology Assessment 2003; 7(33): 1-170 Authors' objectives

This report is a review of the clinical and cost-effectiveness of new and emerging technologies for early, localised prostate cancer. A systematic review was undertaken to identify new and emerging technologies and to evaluate clinical and cost-effectiveness through assessment of the best available evidence. The review aimed to assess

2003 Health Technology Assessment (HTA) Database.

8575. Routine vitamin supplementation to prevent cancer

Routine vitamin supplementation to prevent cancer Routine vitamin supplementation to prevent cancer Routine vitamin supplementation to prevent cancer Ritenbaugh C, Streit K, Helfand M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ritenbaugh C, Streit K, Helfand M. Routine vitamin supplementation to prevent cancer. Rockville: Agency (...) for Healthcare Research and Quality (AHRQ). Preventive Services Task Force Systematic Evidence Review. 2003 Authors' objectives This study aims to assess the evidence on the effectiveness of routine vitamin supplementation to prevent cancer. Project page URL URL for DARE abstract Indexing Status Subject indexing assigned by CRD MeSH Dietary Supplements; Neoplasms /prevention & Vitamins; control Language Published English Country of organisation United States Address for correspondence Center for Outcomes

2003 Health Technology Assessment (HTA) Database.

8576. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation

Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation Ward (...) S, Kaltenthaler E, Cowen J, Brewer N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ward S, Kaltenthaler E, Cowen J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technology Assessment 2003; 7(32): 1-106

2003 Health Technology Assessment (HTA) Database.

8577. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses

A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses Boland A, Haycox A, Bagust A, Fitzsimmons L Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boland A, Haycox A, Bagust A, Fitzsimmons L. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technology Assessment 2003; 7(36): 1-112 Authors' objectives To examine the clinical and cost-effectiveness of image-guided Hickman line

2003 Health Technology Assessment (HTA) Database.

8578. Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer

Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hailey D. Magnetic resonance (...) spectroscopy (MRS) in the management of localized prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2003 Authors' objectives To summarize the available information on the use of magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer. Authors' conclusions The Canadian Cancer Society estimates that 18,800 Canadian men will be diagnosed with prostate cancer in 2003; 4,200 will die. The accuracy of MRS and MRI used in combination

2003 Health Technology Assessment (HTA) Database.

8579. Use of palliative surgery in the treatment of cancer patients

Use of palliative surgery in the treatment of cancer patients Use of palliative surgery in the treatment of cancer patients Use of palliative surgery in the treatment of cancer patients Giercksky K E, Gronbech J E, Hammelbo T, Hirschberg H, Lundar T, Mjaland O, Stangeland L, Soreide J A, Trovik C, Walloe A, Walhqvist R, Wessel N, Haheim L L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Giercksky K E, Gronbech J E, Hammelbo T, Hirschberg H, Lundar T, Mjaland O, Stangeland L, Soreide J A, Trovik C, Walloe A, Walhqvist R, Wessel N, Haheim L L. Use of palliative surgery in the treatment of cancer patients. Oslo: The Norwegian Knowledge Centre for the Health Services (NOKC) 2003: 155 Authors' objectives The aim of this report was to assess the available literature on elective palliative procedures within the surgical specialities

2003 Health Technology Assessment (HTA) Database.

8580. Radiotherapy for cancer

Radiotherapy for cancer Radiotherapy for cancer Radiotherapy for cancer Ask A, Berg G, Bergqvist D, Brorsson B, Cavallin-Stahl E, Ceberg J, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ask A, Berg G, Bergqvist D, Brorsson B, Cavallin-Stahl E, Ceberg J, et al. Radiotherapy for cancer. Stockholm: Swedish Council on Technology (...) Assessment in Health Care (SBU) 2003 Authors' objectives This report updates the previous SBU report 'Radiotherapy for Cancer', published in 1996. The updated report presents a systematic review of the 13 types of cancer that were investigated in the previous report and also addresses two additional types, ie, esophageal cancer and rectal cancer. Authors' conclusions This report lends further support to the role of radiotherapy as an important form of both curative and palliative treatment. At present

2003 Health Technology Assessment (HTA) Database.